RecruitingPhase 1

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

United States56 participantsStarted 2023-05-04

Plain-language summary

Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard treatments, or no standard treatments are available for the participants' cancer. The purpose of this study if to find the highest dose of MQ710 that causes few or mild side effects in participants with a solid tumor cancer diagnosis.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Serum bilirubin ≤1.5 x ULN
✓. AST and ALT ≤2.5 ULN (no liver mets)
✓. AST and ALT ≤5.0 ULN (for patients with liver mets)
✓. Coagulation function adequate (PT and aPTT within x1.5 ULN)
✓. Platelets ≥ 75,000/mm\^2
✓. ANC ≥ 1000/uL

What they're measuring

Safety of MQ710 by review of AEs and SAEs

Timeframe: Up to 2 years

Trial details

NCT IDNCT05859074

SponsorMemorial Sloan Kettering Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-05-04

Contact for this trial

Lara Dunn, MD

646-608-3787 dunnl1@mskcc.org

View on ClinicalTrials.gov More Cutaneous Squamous Cell Carcinoma trials